Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutations
- PMID: 36600087
- DOI: 10.1038/s41585-022-00680-4
Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutations
Abstract
Mutations in the BRCA1 and BRCA2 tumour suppressor genes are associated with prostate cancer risk; however, optimal screening protocols for individuals with these mutations have been a subject of debate. Several prospective studies of prostate cancer incidence and screening among BRCA1/2 mutation carriers have indicated at least a twofold to fourfold increase in prostate cancer risk among carriers of BRCA2 mutations compared with the general population. Moreover, BRCA2 mutations are associated with more aggressive, high-grade disease characteristics at diagnosis, more aggressive clinical behaviour and greater prostate cancer-specific mortality. The risk for BRCA1 mutations seems to be attenuated compared with BRCA2. Prostate-specific antigen (PSA) measurement or prostate magnetic resonance imaging (MRI) alone is an imperfect indicator of clinically significant prostate cancer; therefore, BRCA1/2 mutation carriers might benefit from refined risk stratification strategies. However, the long-term impact of prostate cancer screening is unknown, and the optimal management of BRCA1/2 carriers with prostate cancer has not been defined. Whether timely localized therapy can improve overall survival in the screened population is uncertain. Long-term results of prospective studies are awaited to confirm the optimal screening strategies and benefits of prostate cancer screening among BRCA1/2 mutation carriers, and whether these approaches ultimately have a positive impact on survival and quality of life in these patients.
© 2023. Springer Nature Limited.
Similar articles
-
Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers.Eur Urol. 2019 Dec;76(6):831-842. doi: 10.1016/j.eururo.2019.08.019. Epub 2019 Sep 16. Eur Urol. 2019. PMID: 31537406 Free PMC article.
-
Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study.Eur Urol. 2014 Sep;66(3):489-99. doi: 10.1016/j.eururo.2014.01.003. Epub 2014 Jan 15. Eur Urol. 2014. PMID: 24484606 Free PMC article.
-
Prostate Cancer Screening in a New Era of Genetics.Clin Genitourin Cancer. 2017 Dec;15(6):625-628. doi: 10.1016/j.clgc.2017.05.024. Epub 2017 May 31. Clin Genitourin Cancer. 2017. PMID: 28697982 Review.
-
Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study.BJU Int. 2011 Jan;107(1):28-39. doi: 10.1111/j.1464-410X.2010.09648.x. Epub 2010 Sep 14. BJU Int. 2011. PMID: 20840664 Free PMC article.
-
Implications of High Rates of Metastatic Prostate Cancer in BRCA2 Mutation Carriers.Prostate. 2016 Sep;76(13):1135-45. doi: 10.1002/pros.23204. Epub 2016 May 26. Prostate. 2016. PMID: 27225637 Free PMC article. Review.
Cited by
-
Novel frontiers in urogenital cancers: from molecular bases to preclinical models to tailor personalized treatments in ovarian and prostate cancer patients.J Exp Clin Cancer Res. 2024 May 15;43(1):146. doi: 10.1186/s13046-024-03065-0. J Exp Clin Cancer Res. 2024. PMID: 38750579 Free PMC article. Review.
-
Molecular panorama of therapy resistance in prostate cancer: a pre-clinical and bioinformatics analysis for clinical translation.Cancer Metastasis Rev. 2024 Mar;43(1):229-260. doi: 10.1007/s10555-024-10168-9. Epub 2024 Feb 19. Cancer Metastasis Rev. 2024. PMID: 38374496 Review.
-
Current Management and Future Treatment Strategies for Patients with Metastatic Hormone-Sensitive Prostate Cancer.World J Urol. 2023 Aug;41(8):2005-2006. doi: 10.1007/s00345-023-04542-5. World J Urol. 2023. PMID: 37524851 No abstract available.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous